I was thinking of things like amox-clav, cefalexin, doxycycline, and azithromycin, and screening the patients for risk factors. Oral antibiotics that are commonly used in empirical therapy (i.e., without cultivating a bacterial culture) and have low risks of dangerous side effects. I suspect that, for example, fluoroquinolones would be less likely to pass the cost/benefit test due to their more serious side effects.